18F-5-Fluoroaminosuberic acid as a potential tracer to gauge oxidative stress in breast cancer models

Journal of Nuclear Medicine

Volumn 58, Issue 3, 2017, Pages 367-373

  Yang, Hua ^a   Jenni, Silvia ^a   Colovic, Milena ^a,c   Merkens, Helen ^b   Poleschuk, Carlee ^a   Rodrigo, Isabel ^a   Miao, Qing ^a   Johnson, Bruce F ^d   Rishel, Michael J ^d   Sossi, Vesna ^c   Webster, Jack M ^d   Bénard, Francois ^b,c   Schaffer, Paul ^a,c,e  

^a TRIUMF   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d GE GLOBAL RESEARCH   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

F 18; Oxidative stress; PET; System xC ; Tumor imaging

Indexed keywords

5 FLUOROAMINOSUBERIC ACID F 18; GLUTATHIONE; MALEIC ACID DIETHYL ESTER; RADIOPHARMACEUTICAL AGENT; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 5-FLUOROAMINOSUBERIC ACID; AMINO ACID TRANSPORTER; ANTIOXIDANT; DICARBOXYLIC AMINO ACID; SLC7A11 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; BREAST TUMOR; DIAGNOSTIC IMAGING; FEASIBILITY STUDY; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

AMINO ACID TRANSPORT SYSTEM Y+; AMINO ACIDS, DICARBOXYLIC; ANTIOXIDANTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEASIBILITY STUDIES; HUMANS; OXIDATIVE STRESS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 85014862702     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.116.180661     Document Type: Article

References (27)

1. Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013;32:5191-5198
2. Dayem AA, Choi HY, Kim JH, Cho SG. Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers (Basel). 2010;2:859-884
3. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009;284:13291-13295
4. Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system xc 2: cystine supplier and beyond. Amino Acids. 2012;42:231-246
5. Bridges RJ, Natale NR, Patel SA. System xc2 cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol. 2012;165:20-34
6. Ishii T, Sato H, Miura K, Sagara J, Bannai S. Induction of cystine transport activity by stress. Ann N Y Acad Sci. 1992;663:497-498
7. LoM,Wang YZ, Gout PW. The xc 2 cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215:593-602
8. Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24:450-465
9. Yoshikawa M, Tsuchihashi K, Ishimoto T, et al. xCT inhibition depletes CD44vexpressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013;73:1855-1866
10. Dai L, Cao YY, Chen YH, Parsons C, Qin ZQ. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol. 2014;7:30
11. Doxsee DW, Gout PW, Kurita T, et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007;67:162-171
12. Lay JD, Hong CC, Huang JS, et al. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res. 2007;67: 3878-3887
13. Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR. Sulfasalazineinduced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of doxorubicin. Chemotherapy. 2007;53:210-217
14. Pham AN, Blower PE, Alvarado O, Ravula R, Gout PW, Huang Y. Pharmacogenomic approach reveals a role for the xc 2 cystine/glutamate antiporter in growth and Celastrol resistance of glioma cell lines. J Pharmacol Exp Ther. 2010;332:949-958
15. Müerköster S, Arlt A, Witt M, et al. Usage of the NF-kappa B inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer. 2003;104:469-476
16. Qin Z, Freitas E, Sullivan R, et al. Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog. 2010;6:e1000742
17. Webster JM, Morton CA, Johnson BF, et al. Functional imaging of oxidative stress with a novel PET imaging agent, F-18-5-fluoro-L-aminosuberic acid. J Nucl Med. 2014;55:657-664
18. Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer. 2011;11:262
19. Baek S, Choi CM, Ahn SH, et al. Exploratory clinical trial of (4S)-4-(3-[18F] fluoropropyl)-L-glutamate for imaging xC2 transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res. 2012;18:5427-5437
20. Bannai S. Induction of cystine and glutamate transport activity in human-fibroblasts by diethyl maleate and other electrophilic agents. J Biol Chem. 1984;259:2435-2440
21. Hosoya K, Tomi M, Ohtsuki S, et al. Enhancement of L-cystine transport activity and its relation to xCT gene induction at the blood-brain barrier by diethyl maleate treatment. J Pharmacol Exp Ther. 2002;302:225-231
22. Sasaki H, Sato H, Kuriyama-Matsumura K, et al. Electrophile response elementmediated induction of the cystine/glutamate exchange transporter gene expression. J Biol Chem. 2002;277:44765-44771
23. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483: 603-607
24. Lo M, Ling V, Wang YZ, Gout PW. The xc 2 cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99:464-472
25. Kapushesky M, Emam I, Holloway E, et al. Gene Expression Atlas at the European Bioinformatics Institute. Nucleic Acids Res. 2010;38:D690-D698
26. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27(suppl):S215-S229
27. Koglin N, Mueller A, Berndt M, et al. Specific PET imaging of xC 2 transporter activity using a 18F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism. Clin Cancer Res. 2011;17:6000-6011.